The global influenza vaccines market size is slated to reach USD 7.34 billion by 2026, exhibiting a CAGR of 7.7% during the forecast period. Increasing prevalence of influenza worldwide will be the major driving force behind the growth of this market. According to the World Health Organization (WHO), around 3 to 5 million cases of influenza-based diseases are reported annually across the globe. This has spurred governments to take proactive measures to contain the spread of this deadly disease. Many governments carry out extensive vaccination drives before the flu season begins to immunize people from contracting any such infections, bolstering the seasonal influenza vaccines market demand.

According to a new Fortune Business Insights™ report, titled “Influenza Vaccines Market Size, Share & Industry Analysis, By Type (Inactivated, and Live Attenuated), By Valency (Quadrivalent and Trivalent), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2019-2026”, the value of this market stood at USD 4.05 billion in 2018. In addition to market value, the report provides the following:

Request Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/influenza-vaccine-market-101896

Top Players Profiled:

AstraZeneca
F. Hoffmann-La Roche Ltd
Sanofi
GlaxoSmithKline plc.
Sinovac Biotech Ltd
CSL Limited
Emergent BioSolutions Inc.
BioDiem

Presence of a Few Players to Make Competition Tight

Through its influenza vaccines market report, Fortune Business Insights™ has brought out an in-depth analysis of the competition in this market. The report states that the competitive landscape will be dotted by a few key players who are increasing their investment in enhancing their R&D capacities to widen their product portfolio.

Key Industry Developments:

November 2019: Sanofi received clearance for its Fluzone® High-Dose Quadrivalent from the US Food and Drug Administration (FDA). Containing an additional Influenza B strain, the drug is designed and aimed at treating adults at and over the age of 65.

January 2019: The European Commission green lit Seqirus’s FLUCELVAX® TETRA for marketing in Europe. This is a cell-based quadrivalent influenza vaccine, the first of its kind to be marketed in Europe, which is to be used on people aged 9 years and above.

The global influenza vaccines market size is slated to reach USD 7.34 billion by 2026, exhibiting a CAGR of 7.7% during the forecast period. Increasing prevalence of influenza worldwide will be the major driving force behind the growth of this market. According to the World Health Organization (WHO), around 3 to 5 million cases of influenza-based diseases are reported annually across the globe. This has spurred governments to take proactive measures to contain the spread of this deadly disease. Many governments carry out extensive vaccination drives before the flu season begins to immunize people from contracting any such infections, bolstering the seasonal influenza vaccines market demand.

About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact Us:
Fortune Business Insights Pvt. Ltd. 9th Floor, Icon Tower, Baner - Mahalunge Road, Baner, Pune-411045, Maharashtra, India. Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: mailto:[email protected]